Phase 1 NSCLC Clinical Trials
17 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Regeneron Pharmaceuticals231 enrolled40 locationsNCT04077099
Recruiting
Phase 1Phase 2
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Lung CancerNSCLCBrain Metastases
Joshua Palmer56 enrolled3 locationsNCT05987644
Recruiting
Phase 1Phase 2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ovarian CancerCervical CancerEndometrial Cancer+6 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149
Recruiting
Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled1 locationNCT07397338
Recruiting
Phase 1
SLV-154 Treatment of Metastatic Solid Tumors
Breast Cancer MetastaticOvarian CancerEndometrial Cancer+7 more
Solve Therapeutics70 enrolled9 locationsNCT06771219
Recruiting
Phase 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled12 locationsNCT06922591
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled10 locationsNCT05786924
Recruiting
Phase 1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Advanced Solid TumorCancerNSCLC+5 more
TOLREMO therapeutics AG50 enrolled7 locationsNCT06403436
Recruiting
Phase 1Phase 2
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
NSCLC
Suzhou Junjing BioSciences Co., Ltd.42 enrolled1 locationNCT06940401
Recruiting
Phase 1Phase 2
Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265
Recruiting
Phase 1
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study
NSCLC
Peter MacCallum Cancer Centre, Australia40 enrolled6 locationsNCT05222087
Recruiting
Phase 1
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
NSCLC
National Cancer Center, China20 enrolled1 locationNCT06362980
Recruiting
Phase 1
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NSCLCLeptomeningeal MetastasisLow Dose Radiotherapy+1 more
Sichuan University10 enrolled1 locationNCT06431685
Recruiting
Phase 1
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NSCLCLow Dose RadiotherapyPD-1 Inhibitor+1 more
Sichuan University9 enrolled1 locationNCT05615142